On October 16, 2024, Natarajan Sethuraman, President of Research & Development at Entrada Therapeutics Inc (TRDA, Financial), executed a sale of 600 shares of the company. The transaction was filed through an SEC Filing. Following this sale, the insider now owns 183,216 shares of Entrada Therapeutics Inc.
Entrada Therapeutics Inc (TRDA, Financial) is a biotechnology firm focused on the development of therapies that target intracellular proteins. The company's innovative approach aims to address various severe diseases through its proprietary technology.
Over the past year, Natarajan Sethuraman has sold a total of 24,060 shares and has not made any purchases of the stock. This recent sale is part of a broader trend observed within the company, where insider transactions have predominantly been sales. In the past year, there have been 19 insider sales compared to 6 insider buys.
Shares of Entrada Therapeutics Inc were trading at $18 on the day of the transaction. The company's market cap stands at $648.76 million. Entrada Therapeutics Inc's price-earnings ratio is currently 5.89, which is significantly lower than the industry median of 26.655 and below the company’s historical median.
This insider sale might interest investors tracking insider behaviors as an indicator of the company’s performance and future outlook. For more detailed valuation metrics such as price-sales ratio, price-book ratio, and price-to-free cash flow, further analysis and context should be considered.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
